Using these compounds, we studied whether SLC3031~3035 and SLC3037 at 5μM concentration could inhibit IL-1β release from bone marrow-derived macrophages (BMDMs) in response to MSU, an effector of inflammasome activation in gout (6) in combination with LPS (LPS+MSU). The gene discussed is IL1B; the disease is gout.